Medtronic PLC (NYSE:MDT) is set to report its fiscal fourth quarter 2026 results before the opening bell on Wednesday, June 3.

Analysts expect the Minneapolis, Minnesota-based company to post revenue of $9.61 billion, up 7.6% from the year-ago quarter, and EPS of $1.55, representing a 4.3% decline from the $1.62 reported for the same quarter last year.

Medtronic has entered into an agreement to buy SPR Therapeutics, a manufacturer of peripheral nerve stimulation devices to treat chronic pain, for $650 million in cash. The acquisition will mark Medtronic's third major purchase in 2026 and add to the company's neuromodulation business.

Medtronic shares rose 0.31% to close at $73.75 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

UBS analyst Priya Sachdeva maintained a Neutral rating on the stock, while cutting the price target from $104 to $90 on April 22, 2026. This analyst has an accuracy rate of 73%.

Truist Securities analyst Richard Newitter reiterated the stock at Hold while lowering the price target from $103 to $95 on April 15, 2026. This analyst has an accuracy rate of 64%.

Mizuho analyst Anthony Petrone reaffirmed an Outperform rating on the stock while lowering the price target from $125 to $120 on April 13, 2026. This analyst has an accuracy rate of 65%.

Citigroup analyst Joanne Wuensch maintained the stock with a Buy rating while cutting the price target from $117 to $110 on April 7, 2026. This analyst has an accuracy rate of 67%.

Argus Research analyst David Toung reiterated a Buy rating on the stock while lowering the price target from $125 to 115 on April 6, 2026. This analyst has an accuracy rate of 66%.

Considering buying MDT stock? Here’s what analysts think: